AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
granisetron 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| serotonin receptor antagonists (5-HT3) | 1329 | 109889-09-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | mg | O |
| 3 | mg | P |
| 3.10 | mg | TD |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 100 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 11 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.03 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 60 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 3.70 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 9.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.35 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 5.20 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 29, 1993 | FDA | ROCHE | |
| Feb. 25, 2022 | PMDA | Taiyo Pharma Co Ltd | |
| April 20, 2012 | EMA | Kyowa Kirin Holdings B.V. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 768.28 | 18.65 | 485 | 22474 | 157864 | 90447624 |
| Nausea | 269.70 | 18.65 | 748 | 22211 | 1109568 | 89495920 |
| Neutropenia | 249.96 | 18.65 | 296 | 22663 | 224608 | 90380880 |
| Drug ineffective | 219.53 | 18.65 | 43 | 22916 | 1384255 | 89221233 |
| Neutrophil count decreased | 204.87 | 18.65 | 159 | 22800 | 71373 | 90534115 |
| Anaemia | 159.77 | 18.65 | 305 | 22654 | 352497 | 90252991 |
| Vomiting | 148.66 | 18.65 | 487 | 22472 | 787806 | 89817682 |
| Pyrexia | 144.71 | 18.65 | 430 | 22529 | 660055 | 89945433 |
| Leukopenia | 134.52 | 18.65 | 146 | 22813 | 100564 | 90504924 |
| Death | 130.55 | 18.65 | 328 | 22631 | 456223 | 90149265 |
| Platelet count decreased | 124.23 | 18.65 | 163 | 22796 | 136806 | 90468682 |
| Polyneuropathy | 110.61 | 18.65 | 66 | 22893 | 19275 | 90586213 |
| Joint swelling | 109.99 | 18.65 | 4 | 22955 | 503296 | 90102192 |
| Diarrhoea | 106.28 | 18.65 | 494 | 22465 | 938696 | 89666792 |
| Constipation | 95.71 | 18.65 | 216 | 22743 | 280179 | 90325309 |
| Mucosal inflammation | 90.25 | 18.65 | 91 | 22868 | 57534 | 90547954 |
| Dyspnoea | 84.28 | 18.65 | 442 | 22517 | 880513 | 89724975 |
| White blood cell count decreased | 79.82 | 18.65 | 148 | 22811 | 166961 | 90438527 |
| Rheumatoid arthritis | 78.77 | 18.65 | 3 | 22956 | 362611 | 90242877 |
| Disease progression | 76.42 | 18.65 | 140 | 22819 | 156475 | 90449013 |
| Thrombocytopenia | 74.78 | 18.65 | 164 | 22795 | 208561 | 90396927 |
| Decreased appetite | 74.52 | 18.65 | 237 | 22722 | 376303 | 90229185 |
| Flushing | 73.59 | 18.65 | 101 | 22858 | 88390 | 90517098 |
| Drug intolerance | 72.45 | 18.65 | 13 | 22946 | 447578 | 90157910 |
| Abdominal pain | 71.96 | 18.65 | 242 | 22717 | 395479 | 90210009 |
| Malignant neoplasm progression | 70.03 | 18.65 | 109 | 22850 | 106761 | 90498727 |
| General physical health deterioration | 68.88 | 18.65 | 222 | 22737 | 354893 | 90250595 |
| Hypokalaemia | 66.23 | 18.65 | 119 | 22840 | 130997 | 90474491 |
| Swelling | 61.99 | 18.65 | 15 | 22944 | 419043 | 90186445 |
| Bone pain | 56.50 | 18.65 | 74 | 22885 | 61909 | 90543579 |
| Chest discomfort | 54.46 | 18.65 | 113 | 22846 | 138252 | 90467236 |
| Weight increased | 54.40 | 18.65 | 19 | 22940 | 417908 | 90187580 |
| Pancytopenia | 54.27 | 18.65 | 104 | 22855 | 120159 | 90485329 |
| Neuropathy peripheral | 54.07 | 18.65 | 112 | 22847 | 136858 | 90468630 |
| Tooth erosion | 51.81 | 18.65 | 14 | 22945 | 493 | 90604995 |
| Musculoskeletal stiffness | 51.61 | 18.65 | 7 | 22952 | 296525 | 90308963 |
| Pharyngeal inflammation | 49.67 | 18.65 | 16 | 22943 | 1044 | 90604444 |
| Condition aggravated | 49.29 | 18.65 | 47 | 22912 | 595498 | 90009990 |
| Maternal exposure during pregnancy | 49.26 | 18.65 | 15 | 22944 | 360048 | 90245440 |
| Lymphoedema | 49.26 | 18.65 | 35 | 22924 | 13718 | 90591770 |
| Pericarditis | 47.92 | 18.65 | 6 | 22953 | 270145 | 90335343 |
| Erythema | 46.84 | 18.65 | 146 | 22813 | 229100 | 90376388 |
| Drug hypersensitivity | 46.67 | 18.65 | 30 | 22929 | 463579 | 90141909 |
| Product use issue | 46.50 | 18.65 | 13 | 22946 | 329906 | 90275582 |
| Peripheral swelling | 45.45 | 18.65 | 24 | 22935 | 413082 | 90192406 |
| Palmar-plantar erythrodysaesthesia syndrome | 45.23 | 18.65 | 45 | 22914 | 27978 | 90577510 |
| Duodenal ulcer perforation | 44.34 | 18.65 | 3 | 22956 | 221285 | 90384203 |
| Hepatic enzyme increased | 44.26 | 18.65 | 18 | 22941 | 360718 | 90244770 |
| Tumour pain | 44.20 | 18.65 | 17 | 22942 | 1870 | 90603618 |
| Breast cancer metastatic | 44.06 | 18.65 | 34 | 22925 | 15098 | 90590390 |
| Dysgeusia | 43.69 | 18.65 | 60 | 22899 | 52500 | 90552988 |
| Sepsis | 42.89 | 18.65 | 121 | 22838 | 179693 | 90425795 |
| Bone marrow failure | 41.73 | 18.65 | 46 | 22913 | 32175 | 90573313 |
| Ejection fraction decreased | 40.25 | 18.65 | 41 | 22918 | 26212 | 90579276 |
| Ileus | 39.30 | 18.65 | 33 | 22926 | 16513 | 90588975 |
| Abdominal discomfort | 39.09 | 18.65 | 38 | 22921 | 477290 | 90128198 |
| Wound | 39.02 | 18.65 | 14 | 22945 | 302966 | 90302522 |
| Nasopharyngitis | 38.75 | 18.65 | 28 | 22931 | 407076 | 90198412 |
| Discomfort | 38.30 | 18.65 | 11 | 22948 | 274324 | 90331164 |
| Pulpitis dental | 38 | 18.65 | 13 | 22946 | 1023 | 90604465 |
| Asthma | 37.11 | 18.65 | 8 | 22951 | 242152 | 90363336 |
| Epistaxis | 36.42 | 18.65 | 72 | 22887 | 85053 | 90520435 |
| Serotonin syndrome | 35.71 | 18.65 | 46 | 22913 | 37841 | 90567647 |
| Cough | 35.65 | 18.65 | 186 | 22773 | 368776 | 90236712 |
| Interstitial lung disease | 35.60 | 18.65 | 67 | 22892 | 76338 | 90529150 |
| Tachycardia | 35.55 | 18.65 | 104 | 22855 | 157569 | 90447919 |
| Disseminated intravascular coagulation | 35.53 | 18.65 | 35 | 22924 | 21503 | 90583985 |
| Impaired healing | 35.36 | 18.65 | 8 | 22951 | 234191 | 90371297 |
| Therapeutic product effect incomplete | 35.13 | 18.65 | 4 | 22955 | 193892 | 90411596 |
| Product dose omission issue | 35.05 | 18.65 | 15 | 22944 | 291672 | 90313816 |
| Sinusitis | 33.43 | 18.65 | 23 | 22936 | 343065 | 90262423 |
| Respiratory depth decreased | 33.11 | 18.65 | 6 | 22953 | 29 | 90605459 |
| Mucosal dryness | 32.69 | 18.65 | 16 | 22943 | 3151 | 90602337 |
| Periodontitis | 32.56 | 18.65 | 17 | 22942 | 3836 | 90601652 |
| Exposure during pregnancy | 32.47 | 18.65 | 10 | 22949 | 238400 | 90367088 |
| Asthenia | 32.01 | 18.65 | 238 | 22721 | 533513 | 90071975 |
| Systemic infection | 31.82 | 18.65 | 18 | 22941 | 4757 | 90600731 |
| Hepatic function abnormal | 31.41 | 18.65 | 48 | 22911 | 46240 | 90559248 |
| Venous thrombosis limb | 31.34 | 18.65 | 16 | 22943 | 3446 | 90602042 |
| Toxicity to various agents | 31.23 | 18.65 | 17 | 22942 | 287829 | 90317659 |
| Cachexia | 30.56 | 18.65 | 20 | 22939 | 6858 | 90598630 |
| Oesophagitis | 30.27 | 18.65 | 29 | 22930 | 17220 | 90588268 |
| Chills | 29.70 | 18.65 | 87 | 22872 | 131894 | 90473594 |
| Gastrointestinal disorder | 29.58 | 18.65 | 14 | 22945 | 256673 | 90348815 |
| Ultrasound foetal abnormal | 29.41 | 18.65 | 7 | 22952 | 146 | 90605342 |
| Dysphagia | 29.18 | 18.65 | 78 | 22881 | 112200 | 90493288 |
| Pneumonitis | 28.84 | 18.65 | 45 | 22914 | 44125 | 90561363 |
| Dehydration | 28.52 | 18.65 | 111 | 22848 | 194336 | 90411152 |
| Pleural effusion | 28.30 | 18.65 | 77 | 22882 | 111914 | 90493574 |
| Gastroenteritis radiation | 28.23 | 18.65 | 9 | 22950 | 568 | 90604920 |
| Cytomegalovirus test positive | 27.95 | 18.65 | 15 | 22944 | 3576 | 90601912 |
| Blister | 27.75 | 18.65 | 15 | 22944 | 254983 | 90350505 |
| Ascites | 27.57 | 18.65 | 46 | 22913 | 47694 | 90557794 |
| Liver injury | 27.46 | 18.65 | 5 | 22954 | 170562 | 90434926 |
| Neutropenic sepsis | 27.22 | 18.65 | 28 | 22931 | 18102 | 90587386 |
| Metastases to liver | 27.19 | 18.65 | 35 | 22924 | 28772 | 90576716 |
| Chronic hepatitis B | 27.09 | 18.65 | 8 | 22951 | 390 | 90605098 |
| Folliculitis | 27.06 | 18.65 | 9 | 22950 | 204344 | 90401144 |
| Psoriasis | 26.89 | 18.65 | 3 | 22956 | 147751 | 90457737 |
| Tumour lysis syndrome | 25.99 | 18.65 | 22 | 22937 | 11130 | 90594358 |
| Migraine | 25.90 | 18.65 | 8 | 22951 | 190384 | 90415104 |
| Mobility decreased | 25.51 | 18.65 | 16 | 22943 | 250718 | 90354770 |
| Arthralgia | 24.97 | 18.65 | 107 | 22852 | 778415 | 89827073 |
| Sensation of foreign body | 24.66 | 18.65 | 17 | 22942 | 6349 | 90599139 |
| Fatigue | 24.51 | 18.65 | 419 | 22540 | 1153604 | 89451884 |
| Septic shock | 24.48 | 18.65 | 61 | 22898 | 84099 | 90521389 |
| Lower respiratory tract infection | 24.14 | 18.65 | 17 | 22942 | 250642 | 90354846 |
| Hepatic failure | 23.91 | 18.65 | 39 | 22920 | 39689 | 90565799 |
| Renal pain | 23.83 | 18.65 | 18 | 22941 | 7741 | 90597747 |
| Intestinal perforation | 23.72 | 18.65 | 23 | 22936 | 13858 | 90591630 |
| Mitral valve disease | 23.57 | 18.65 | 12 | 22947 | 2570 | 90602918 |
| Anaphylactic shock | 23.18 | 18.65 | 34 | 22925 | 31583 | 90573905 |
| Sleep disorder | 22.51 | 18.65 | 11 | 22948 | 198019 | 90407469 |
| Dysaesthesia pharynx | 22.46 | 18.65 | 6 | 22953 | 202 | 90605286 |
| Subileus | 22.31 | 18.65 | 13 | 22946 | 3631 | 90601857 |
| Onychalgia | 22.14 | 18.65 | 9 | 22950 | 1145 | 90604343 |
| Fall | 21.75 | 18.65 | 57 | 22902 | 481753 | 90123735 |
| Inflammation | 21.74 | 18.65 | 9 | 22950 | 178583 | 90426905 |
| Contusion | 21.72 | 18.65 | 19 | 22940 | 251197 | 90354291 |
| Acute interstitial pneumonitis | 21.43 | 18.65 | 8 | 22951 | 811 | 90604677 |
| Osteochondrosis | 21.11 | 18.65 | 10 | 22949 | 1833 | 90603655 |
| Enterocolitis | 21.04 | 18.65 | 19 | 22940 | 10471 | 90595017 |
| Memory impairment | 20.88 | 18.65 | 12 | 22947 | 197232 | 90408256 |
| Aortitis | 20.78 | 18.65 | 9 | 22950 | 1341 | 90604147 |
| Flank pain | 20.78 | 18.65 | 25 | 22934 | 19197 | 90586291 |
| Vertigo | 20.72 | 18.65 | 51 | 22908 | 69760 | 90535728 |
| Laryngospasm | 20.70 | 18.65 | 12 | 22947 | 3321 | 90602167 |
| Tachypnoea | 20.28 | 18.65 | 26 | 22933 | 21283 | 90584205 |
| Gastrointestinal perforation | 20.24 | 18.65 | 13 | 22946 | 4319 | 90601169 |
| Acute myeloid leukaemia recurrent | 20.07 | 18.65 | 10 | 22949 | 2047 | 90603441 |
| Mucosal disorder | 19.97 | 18.65 | 11 | 22948 | 2760 | 90602728 |
| Ill-defined disorder | 19.93 | 18.65 | 11 | 22948 | 184880 | 90420608 |
| Back pain | 19.87 | 18.65 | 143 | 22816 | 317032 | 90288456 |
| Gastroenteropancreatic neuroendocrine tumour disease | 19.73 | 18.65 | 4 | 22955 | 38 | 90605450 |
| Cystitis haemorrhagic | 19.67 | 18.65 | 14 | 22945 | 5499 | 90599989 |
| Confusional state | 19.55 | 18.65 | 43 | 22916 | 386162 | 90219326 |
| Cytopenia | 19.36 | 18.65 | 23 | 22936 | 17426 | 90588062 |
| Bacteraemia | 19.35 | 18.65 | 26 | 22933 | 22274 | 90583214 |
| Metastases to central nervous system | 19.26 | 18.65 | 23 | 22936 | 17519 | 90587969 |
| Lymphocyte count decreased | 19.21 | 18.65 | 33 | 22926 | 35017 | 90570471 |
| Oral candidiasis | 18.94 | 18.65 | 33 | 22926 | 35422 | 90570066 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 382.82 | 17.19 | 427 | 17352 | 185276 | 42418280 |
| Drug ineffective | 156.77 | 17.19 | 36 | 17743 | 630161 | 41973395 |
| Neutrophil count decreased | 105.34 | 17.19 | 131 | 17648 | 63284 | 42540272 |
| Pyrexia | 99.10 | 17.19 | 374 | 17405 | 393668 | 42209888 |
| White blood cell count decreased | 84.44 | 17.19 | 159 | 17620 | 110237 | 42493319 |
| Platelet count decreased | 81.54 | 17.19 | 179 | 17600 | 138402 | 42465154 |
| Neutropenia | 75.72 | 17.19 | 218 | 17561 | 199213 | 42404343 |
| Leukopenia | 69.11 | 17.19 | 117 | 17662 | 74629 | 42528927 |
| Anaemia | 67.74 | 17.19 | 263 | 17516 | 280015 | 42323541 |
| Nausea | 66.10 | 17.19 | 333 | 17446 | 396466 | 42207090 |
| Vomiting | 59.05 | 17.19 | 258 | 17521 | 289465 | 42314091 |
| Thrombocytopenia | 58.23 | 17.19 | 193 | 17586 | 190086 | 42413470 |
| General physical health deterioration | 55.09 | 17.19 | 163 | 17616 | 151083 | 42452473 |
| Stomatitis | 54.97 | 17.19 | 85 | 17694 | 50244 | 42553312 |
| Mucosal inflammation | 50.62 | 17.19 | 81 | 17698 | 49293 | 42554263 |
| Decreased appetite | 50.50 | 17.19 | 186 | 17593 | 192951 | 42410605 |
| Mucosal disorder | 49.07 | 17.19 | 22 | 17757 | 2152 | 42601404 |
| Constipation | 49.07 | 17.19 | 164 | 17615 | 162127 | 42441429 |
| Diarrhoea | 47.31 | 17.19 | 341 | 17438 | 460508 | 42143048 |
| Disseminated intravascular coagulation | 45.64 | 17.19 | 54 | 17725 | 24740 | 42578816 |
| Polyneuropathy | 43.55 | 17.19 | 46 | 17733 | 18615 | 42584941 |
| Interstitial lung disease | 40.15 | 17.19 | 96 | 17683 | 78366 | 42525190 |
| Product dose omission issue | 39.80 | 17.19 | 8 | 17771 | 154357 | 42449199 |
| Sepsis | 39.37 | 17.19 | 176 | 17603 | 199158 | 42404398 |
| Fall | 38.87 | 17.19 | 25 | 17754 | 234495 | 42369061 |
| Oesophagitis | 38.12 | 17.19 | 39 | 17740 | 15208 | 42588348 |
| Toxicity to various agents | 33.33 | 17.19 | 28 | 17751 | 229108 | 42374448 |
| Pneumonitis | 30.49 | 17.19 | 59 | 17720 | 41659 | 42561897 |
| Arthralgia | 29.94 | 17.19 | 25 | 17754 | 205213 | 42398343 |
| Systemic infection | 28.84 | 17.19 | 21 | 17758 | 5184 | 42598372 |
| Anaphylactic reaction | 28.29 | 17.19 | 58 | 17721 | 42685 | 42560871 |
| Pneumonia | 28.17 | 17.19 | 284 | 17495 | 421865 | 42181691 |
| Drug therapeutic incompatibility | 27.58 | 17.19 | 7 | 17772 | 114 | 42603442 |
| Blast cell count increased | 26.77 | 17.19 | 12 | 17767 | 1173 | 42602383 |
| Hypokalaemia | 26.73 | 17.19 | 78 | 17701 | 71643 | 42531913 |
| Aortitis | 26.26 | 17.19 | 10 | 17769 | 646 | 42602910 |
| Hypoalbuminaemia | 25.48 | 17.19 | 32 | 17747 | 15578 | 42587978 |
| Radiation oesophagitis | 25.31 | 17.19 | 9 | 17770 | 479 | 42603077 |
| Nail bed inflammation | 24.75 | 17.19 | 7 | 17772 | 175 | 42603381 |
| Insulin autoimmune syndrome | 24.53 | 17.19 | 9 | 17770 | 524 | 42603032 |
| Palmar-plantar erythrodysaesthesia syndrome | 24.21 | 17.19 | 36 | 17743 | 20546 | 42583010 |
| Antithrombin III decreased | 23.88 | 17.19 | 9 | 17770 | 565 | 42602991 |
| Fluid imbalance | 23.80 | 17.19 | 8 | 17771 | 359 | 42603197 |
| Non-small cell lung cancer | 22.97 | 17.19 | 18 | 17761 | 4956 | 42598600 |
| Subclavian artery occlusion | 22.48 | 17.19 | 6 | 17773 | 120 | 42603436 |
| Pancytopenia | 22.48 | 17.19 | 103 | 17676 | 117640 | 42485916 |
| Myocardial infarction | 22.24 | 17.19 | 12 | 17767 | 123997 | 42479559 |
| Dehydration | 22.06 | 17.19 | 117 | 17662 | 141650 | 42461906 |
| Laryngeal leukoplakia | 21.51 | 17.19 | 5 | 17774 | 55 | 42603501 |
| Hepatic infection | 21.32 | 17.19 | 9 | 17770 | 761 | 42602795 |
| Tumour perforation | 21.10 | 17.19 | 8 | 17771 | 511 | 42603045 |
| Paronychia | 20.96 | 17.19 | 16 | 17763 | 4239 | 42599317 |
| Autoimmune colitis | 20.93 | 17.19 | 10 | 17769 | 1131 | 42602425 |
| Blood lactate dehydrogenase increased | 20.43 | 17.19 | 38 | 17741 | 26043 | 42577513 |
| Ileus | 20.43 | 17.19 | 32 | 17747 | 19107 | 42584449 |
| Dermatitis acneiform | 19.71 | 17.19 | 20 | 17759 | 7719 | 42595837 |
| Staphylococcal sepsis | 19.59 | 17.19 | 24 | 17755 | 11390 | 42592166 |
| Cytokine release syndrome | 19.12 | 17.19 | 51 | 17728 | 44476 | 42559080 |
| Drug intolerance | 19.05 | 17.19 | 5 | 17774 | 80419 | 42523137 |
| Hospitalisation | 18.84 | 17.19 | 4 | 17775 | 74326 | 42529230 |
| Joint swelling | 18.65 | 17.19 | 3 | 17776 | 68019 | 42535537 |
| Alopecia | 18.52 | 17.19 | 39 | 17740 | 29237 | 42574319 |
| Taste disorder | 18.40 | 17.19 | 22 | 17757 | 10185 | 42593371 |
| Hepatic function abnormal | 18.18 | 17.19 | 55 | 17724 | 51512 | 42552044 |
| Peripheral sensory neuropathy | 17.66 | 17.19 | 20 | 17759 | 8742 | 42594814 |
| Flushing | 17.53 | 17.19 | 44 | 17735 | 36984 | 42566572 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 1082.16 | 17.23 | 854 | 34227 | 315913 | 110238305 |
| Neutrophil count decreased | 295.98 | 17.23 | 270 | 34811 | 120671 | 110433547 |
| Drug ineffective | 279.68 | 17.23 | 70 | 35011 | 1520470 | 109033748 |
| Nausea | 258.32 | 17.23 | 917 | 34164 | 1234773 | 109319445 |
| Neutropenia | 251.03 | 17.23 | 436 | 34645 | 374184 | 110180034 |
| Platelet count decreased | 224.97 | 17.23 | 319 | 34762 | 230124 | 110324094 |
| Pyrexia | 212.04 | 17.23 | 695 | 34386 | 897570 | 109656648 |
| Anaemia | 198.85 | 17.23 | 495 | 34586 | 546591 | 110007627 |
| Leukopenia | 174.04 | 17.23 | 225 | 34856 | 148566 | 110405652 |
| White blood cell count decreased | 170.69 | 17.23 | 280 | 34801 | 229110 | 110325108 |
| Vomiting | 152.56 | 17.23 | 631 | 34450 | 910044 | 109644174 |
| Polyneuropathy | 148.23 | 17.23 | 104 | 34977 | 31908 | 110522310 |
| Mucosal inflammation | 134.28 | 17.23 | 159 | 34922 | 95982 | 110458236 |
| Thrombocytopenia | 131.06 | 17.23 | 320 | 34761 | 348565 | 110205653 |
| Diarrhoea | 127.77 | 17.23 | 703 | 34378 | 1138802 | 109415416 |
| Joint swelling | 115.82 | 17.23 | 6 | 35075 | 442839 | 110111379 |
| Constipation | 105.60 | 17.23 | 300 | 34781 | 357486 | 110196732 |
| Drug intolerance | 96.20 | 17.23 | 9 | 35072 | 406503 | 110147715 |
| Sepsis | 96.11 | 17.23 | 274 | 34807 | 327072 | 110227146 |
| Flushing | 89.05 | 17.23 | 136 | 34945 | 104600 | 110449618 |
| Hypokalaemia | 88.09 | 17.23 | 185 | 34896 | 182263 | 110371955 |
| Decreased appetite | 86.73 | 17.23 | 339 | 34742 | 475507 | 110078711 |
| General physical health deterioration | 85.78 | 17.23 | 313 | 34768 | 424982 | 110129236 |
| Oesophagitis | 77.86 | 17.23 | 68 | 35013 | 28647 | 110525571 |
| Malignant neoplasm progression | 75.12 | 17.23 | 169 | 34912 | 174398 | 110379820 |
| Treatment failure | 74.91 | 17.23 | 3 | 35078 | 277231 | 110276987 |
| Interstitial lung disease | 74.00 | 17.23 | 147 | 34934 | 139187 | 110415031 |
| Disseminated intravascular coagulation | 72.56 | 17.23 | 77 | 35004 | 41209 | 110513009 |
| Dyspnoea | 70.27 | 17.23 | 594 | 34487 | 1106278 | 109447940 |
| Pancytopenia | 68.95 | 17.23 | 183 | 34898 | 209430 | 110344788 |
| Arthralgia | 67.71 | 17.23 | 89 | 34992 | 779543 | 109774675 |
| Peripheral swelling | 65.82 | 17.23 | 23 | 35058 | 404011 | 110150207 |
| Completed suicide | 64.24 | 17.23 | 3 | 35078 | 242378 | 110311840 |
| Systemic infection | 62.70 | 17.23 | 39 | 35042 | 9780 | 110544438 |
| Product dose omission issue | 62.40 | 17.23 | 13 | 35068 | 321769 | 110232449 |
| Palmar-plantar erythrodysaesthesia syndrome | 60.83 | 17.23 | 70 | 35011 | 40955 | 110513263 |
| Drug hypersensitivity | 59.70 | 17.23 | 35 | 35046 | 454055 | 110100163 |
| Musculoskeletal stiffness | 57.02 | 17.23 | 10 | 35071 | 279812 | 110274406 |
| Fall | 56.45 | 17.23 | 65 | 35016 | 603417 | 109950801 |
| Therapeutic product effect incomplete | 55.55 | 17.23 | 4 | 35077 | 223801 | 110330417 |
| Ileus | 55.22 | 17.23 | 58 | 35023 | 30671 | 110523547 |
| Pneumonitis | 54.91 | 17.23 | 92 | 34989 | 76439 | 110477779 |
| Pulpitis dental | 54.62 | 17.23 | 20 | 35061 | 1529 | 110552689 |
| Weight increased | 54.24 | 17.23 | 33 | 35048 | 419611 | 110134607 |
| Toxicity to various agents | 53.94 | 17.23 | 44 | 35037 | 480511 | 110073707 |
| Bone marrow failure | 51.83 | 17.23 | 77 | 35004 | 57771 | 110496447 |
| Mucosal disorder | 51.35 | 17.23 | 26 | 35055 | 4391 | 110549827 |
| Condition aggravated | 50.45 | 17.23 | 98 | 34983 | 734738 | 109819480 |
| Abdominal pain | 49.63 | 17.23 | 305 | 34776 | 512684 | 110041534 |
| Hepatic function abnormal | 49.57 | 17.23 | 96 | 34985 | 89199 | 110465019 |
| Pericarditis | 48.87 | 17.23 | 6 | 35075 | 219108 | 110335110 |
| Nasopharyngitis | 48.24 | 17.23 | 33 | 35048 | 394328 | 110159890 |
| Blister | 46.60 | 17.23 | 8 | 35073 | 227368 | 110326850 |
| Tooth erosion | 46.20 | 17.23 | 13 | 35068 | 423 | 110553795 |
| Aortitis | 46.09 | 17.23 | 19 | 35062 | 1996 | 110552222 |
| Mobility decreased | 45.19 | 17.23 | 10 | 35071 | 237412 | 110316806 |
| Swelling | 44.80 | 17.23 | 28 | 35053 | 351013 | 110203205 |
| Dehydration | 44.39 | 17.23 | 191 | 34890 | 279320 | 110274898 |
| Pharyngeal inflammation | 42.07 | 17.23 | 17 | 35064 | 1697 | 110552521 |
| Cytokine release syndrome | 42.00 | 17.23 | 78 | 35003 | 70228 | 110483990 |
| Injury | 41.70 | 17.23 | 4 | 35077 | 177261 | 110376957 |
| Type 2 diabetes mellitus | 41.69 | 17.23 | 4 | 35077 | 177228 | 110376990 |
| Maternal exposure during pregnancy | 40.65 | 17.23 | 15 | 35066 | 254868 | 110299350 |
| Wound | 40.53 | 17.23 | 12 | 35069 | 234425 | 110319793 |
| Sinusitis | 40.21 | 17.23 | 22 | 35059 | 296666 | 110257552 |
| Enterocolitis | 39.96 | 17.23 | 39 | 35042 | 18910 | 110535308 |
| Duodenal ulcer perforation | 39.30 | 17.23 | 5 | 35076 | 177695 | 110376523 |
| Tachycardia | 39.20 | 17.23 | 159 | 34922 | 226486 | 110327732 |
| Tumour pain | 39.04 | 17.23 | 19 | 35062 | 2948 | 110551270 |
| Product use issue | 38.22 | 17.23 | 26 | 35055 | 311669 | 110242549 |
| Chills | 37.27 | 17.23 | 139 | 34942 | 190441 | 110363777 |
| Discomfort | 37.10 | 17.23 | 11 | 35070 | 214696 | 110339522 |
| Radiation oesophagitis | 37.01 | 17.23 | 13 | 35068 | 881 | 110553337 |
| Blood cholesterol increased | 36.78 | 17.23 | 7 | 35074 | 184778 | 110369440 |
| Hypoalbuminaemia | 35.69 | 17.23 | 45 | 35036 | 28929 | 110525289 |
| Neutropenic sepsis | 35.12 | 17.23 | 46 | 35035 | 30700 | 110523518 |
| Tumour lysis syndrome | 35.06 | 17.23 | 46 | 35035 | 30755 | 110523463 |
| Large intestine perforation | 34.64 | 17.23 | 34 | 35047 | 16595 | 110537623 |
| Neuropathy peripheral | 34.43 | 17.23 | 130 | 34951 | 179147 | 110375071 |
| Disease progression | 33.67 | 17.23 | 160 | 34921 | 243874 | 110310344 |
| Stomatitis | 33.60 | 17.23 | 172 | 34909 | 270070 | 110284148 |
| Pneumonia | 32.80 | 17.23 | 423 | 34658 | 876291 | 109677927 |
| Epistaxis | 32.40 | 17.23 | 103 | 34978 | 130269 | 110423949 |
| Bacteraemia | 31.80 | 17.23 | 52 | 35029 | 42338 | 110511880 |
| Respiratory depth decreased | 31.77 | 17.23 | 6 | 35075 | 29 | 110554189 |
| Breast cancer metastatic | 31.36 | 17.23 | 27 | 35054 | 11154 | 110543064 |
| Gastrointestinal disorder | 31.27 | 17.23 | 19 | 35062 | 241933 | 110312285 |
| Myocardial infarction | 31.14 | 17.23 | 11 | 35070 | 192072 | 110362146 |
| Abdominal discomfort | 31.11 | 17.23 | 48 | 35033 | 393810 | 110160408 |
| Ultrasound foetal abnormal | 31.02 | 17.23 | 7 | 35074 | 90 | 110554128 |
| Hepatic enzyme increased | 30.58 | 17.23 | 34 | 35047 | 320858 | 110233360 |
| Asthma | 30.52 | 17.23 | 21 | 35060 | 250270 | 110303948 |
| Tachypnoea | 30.47 | 17.23 | 49 | 35032 | 39346 | 110514872 |
| Dysgeusia | 30.35 | 17.23 | 68 | 35013 | 69917 | 110484301 |
| Dermatitis acneiform | 30.33 | 17.23 | 28 | 35053 | 12667 | 110541551 |
| C-reactive protein abnormal | 30.31 | 17.23 | 3 | 35078 | 129692 | 110424526 |
| Lymphoedema | 30.13 | 17.23 | 30 | 35051 | 14899 | 110539319 |
| Neutropenic colitis | 30.08 | 17.23 | 23 | 35058 | 8042 | 110546176 |
| Liver injury | 29.30 | 17.23 | 6 | 35075 | 150407 | 110403811 |
| Migraine | 29.28 | 17.23 | 9 | 35072 | 171643 | 110382575 |
| Memory impairment | 29.10 | 17.23 | 13 | 35068 | 196931 | 110357287 |
| Venous thrombosis limb | 28.87 | 17.23 | 19 | 35062 | 5246 | 110548972 |
| Chest discomfort | 28.51 | 17.23 | 120 | 34961 | 173728 | 110380490 |
| Inflammation | 28.17 | 17.23 | 13 | 35068 | 193225 | 110360993 |
| Exposure during pregnancy | 28.16 | 17.23 | 9 | 35072 | 167415 | 110386803 |
| Bursitis | 27.90 | 17.23 | 4 | 35077 | 129914 | 110424304 |
| Confusional state | 27.57 | 17.23 | 68 | 35013 | 468612 | 110085606 |
| Impaired healing | 27.51 | 17.23 | 14 | 35067 | 196703 | 110357515 |
| Blood lactate dehydrogenase increased | 27.50 | 17.23 | 50 | 35031 | 44284 | 110509934 |
| Drug therapeutic incompatibility | 27.37 | 17.23 | 7 | 35074 | 157 | 110554061 |
| Peripheral sensory neuropathy | 27.35 | 17.23 | 30 | 35051 | 16650 | 110537568 |
| Engraftment syndrome | 27.32 | 17.23 | 13 | 35068 | 1919 | 110552299 |
| Antithrombin III decreased | 27.16 | 17.23 | 9 | 35072 | 511 | 110553707 |
| Pain | 26.90 | 17.23 | 185 | 34896 | 954770 | 109599448 |
| Periodontitis | 26.65 | 17.23 | 18 | 35063 | 5190 | 110549028 |
| Psoriasis | 26.42 | 17.23 | 6 | 35075 | 139987 | 110414231 |
| Staphylococcal sepsis | 26.24 | 17.23 | 30 | 35051 | 17424 | 110536794 |
| Non-small cell lung cancer | 26.07 | 17.23 | 21 | 35060 | 7914 | 110546304 |
| Venoocclusive disease | 25.66 | 17.23 | 19 | 35062 | 6331 | 110547887 |
| Colitis | 25.57 | 17.23 | 81 | 35000 | 102242 | 110451976 |
| Hepatic infection | 25.54 | 17.23 | 11 | 35070 | 1288 | 110552930 |
| Therapy non-responder | 25.51 | 17.23 | 9 | 35072 | 157298 | 110396920 |
| Cystitis haemorrhagic | 25.50 | 17.23 | 25 | 35056 | 12184 | 110542034 |
| Erythema | 25.48 | 17.23 | 169 | 34912 | 291278 | 110262940 |
| Colony stimulating factor therapy | 25.30 | 17.23 | 9 | 35072 | 633 | 110553585 |
| Sleep disorder | 25.11 | 17.23 | 16 | 35065 | 198628 | 110355590 |
| Septic shock | 24.49 | 17.23 | 107 | 34974 | 157421 | 110396797 |
| Osteoarthritis | 24.08 | 17.23 | 14 | 35067 | 182609 | 110371609 |
| Insulin autoimmune syndrome | 24.03 | 17.23 | 9 | 35072 | 733 | 110553485 |
| Dysaesthesia pharynx | 23.86 | 17.23 | 7 | 35074 | 265 | 110553953 |
| Immune-mediated enterocolitis | 23.44 | 17.23 | 22 | 35059 | 10163 | 110544055 |
| Intestinal perforation | 23.40 | 17.23 | 31 | 35050 | 20913 | 110533305 |
| Gastroenteritis radiation | 23.29 | 17.23 | 9 | 35072 | 799 | 110553419 |
| Blast cell count increased | 23.11 | 17.23 | 11 | 35070 | 1626 | 110552592 |
| Lower respiratory tract infection | 22.89 | 17.23 | 26 | 35055 | 243080 | 110311138 |
| Enterocolitis infectious | 22.80 | 17.23 | 14 | 35067 | 3430 | 110550788 |
| Laryngeal leukoplakia | 22.79 | 17.23 | 5 | 35076 | 56 | 110554162 |
| Pleural effusion | 22.70 | 17.23 | 114 | 34967 | 177595 | 110376623 |
| Chronic hepatitis B | 22.54 | 17.23 | 8 | 35073 | 559 | 110553659 |
| Subclavian artery occlusion | 22.22 | 17.23 | 6 | 35075 | 167 | 110554051 |
| Ill-defined disorder | 22.18 | 17.23 | 11 | 35070 | 156842 | 110397376 |
| Proteinuria | 22.17 | 17.23 | 43 | 35038 | 39975 | 110514243 |
| Arthritis | 21.88 | 17.23 | 13 | 35068 | 167573 | 110386645 |
| Tumour perforation | 21.53 | 17.23 | 8 | 35073 | 637 | 110553581 |
| Gastroenteropancreatic neuroendocrine tumour disease | 21.44 | 17.23 | 5 | 35076 | 75 | 110554143 |
| Wheezing | 21.22 | 17.23 | 30 | 35051 | 255200 | 110299018 |
| Subileus | 21.07 | 17.23 | 17 | 35064 | 6420 | 110547798 |
| Stress | 20.94 | 17.23 | 4 | 35077 | 105344 | 110448874 |
| Gastrointestinal perforation | 20.90 | 17.23 | 18 | 35063 | 7438 | 110546780 |
| Fluid imbalance | 20.88 | 17.23 | 8 | 35073 | 694 | 110553524 |
| Serotonin syndrome | 20.81 | 17.23 | 53 | 35028 | 59100 | 110495118 |
| Intentional product use issue | 20.75 | 17.23 | 29 | 35052 | 247877 | 110306341 |
| Hepatic failure | 20.57 | 17.23 | 58 | 35023 | 68681 | 110485537 |
| Onychalgia | 20.32 | 17.23 | 9 | 35072 | 1128 | 110553090 |
| Drug ineffective for unapproved indication | 20.24 | 17.23 | 4 | 35077 | 102834 | 110451384 |
| Dysaesthesia | 20.15 | 17.23 | 17 | 35064 | 6830 | 110547388 |
| Febrile infection | 19.54 | 17.23 | 14 | 35067 | 4434 | 110549784 |
| Gastrooesophageal reflux disease | 19.52 | 17.23 | 17 | 35064 | 179959 | 110374259 |
| Hyperglycaemia | 19.14 | 17.23 | 65 | 35016 | 85025 | 110469193 |
| Anaphylactic shock | 18.99 | 17.23 | 47 | 35034 | 51499 | 110502719 |
| Cachexia | 18.96 | 17.23 | 22 | 35059 | 12983 | 110541235 |
| Oral candidiasis | 18.86 | 17.23 | 43 | 35038 | 44717 | 110509501 |
| Lymphocyte count decreased | 18.82 | 17.23 | 50 | 35031 | 57193 | 110497025 |
| Acute graft versus host disease in skin | 18.81 | 17.23 | 20 | 35061 | 10720 | 110543498 |
| Bone pain | 18.56 | 17.23 | 54 | 35027 | 65079 | 110489139 |
| Aplastic anaemia | 18.48 | 17.23 | 30 | 35051 | 24278 | 110529940 |
| Incorrect dose administered | 18.47 | 17.23 | 5 | 35076 | 103636 | 110450582 |
| Vertigo | 18.36 | 17.23 | 65 | 35016 | 86805 | 110467413 |
| Paronychia | 18.29 | 17.23 | 20 | 35061 | 11061 | 110543157 |
| Autoimmune colitis | 18.28 | 17.23 | 10 | 35071 | 1975 | 110552243 |
| Death | 18.19 | 17.23 | 317 | 34764 | 698552 | 109855666 |
| Night sweats | 18.05 | 17.23 | 10 | 35071 | 133973 | 110420245 |
| Anaphylactic reaction | 18.04 | 17.23 | 78 | 35003 | 114222 | 110439996 |
| Intracranial tumour haemorrhage | 17.94 | 17.23 | 7 | 35074 | 637 | 110553581 |
| Sensation of foreign body | 17.92 | 17.23 | 17 | 35064 | 7958 | 110546260 |
| Injection site pain | 17.89 | 17.23 | 18 | 35063 | 177904 | 110376314 |
| Circulatory collapse | 17.78 | 17.23 | 41 | 35040 | 42952 | 110511266 |
| Mucosal dryness | 17.78 | 17.23 | 13 | 35068 | 4250 | 110549968 |
| Vulvovaginal dryness | 17.76 | 17.23 | 11 | 35070 | 2736 | 110551482 |
| Cytomegalovirus test positive | 17.75 | 17.23 | 16 | 35065 | 7020 | 110547198 |
| Electrocardiogram ST segment elevation | 17.74 | 17.23 | 18 | 35063 | 9142 | 110545076 |
| Restrictive cardiomyopathy | 17.69 | 17.23 | 8 | 35073 | 1053 | 110553165 |
| Road traffic accident | 17.66 | 17.23 | 6 | 35075 | 107392 | 110446826 |
| Hypotension | 17.57 | 17.23 | 248 | 34833 | 523601 | 110030617 |
| COVID-19 | 17.36 | 17.23 | 32 | 35049 | 245028 | 110309190 |
| Throat tightness | 17.36 | 17.23 | 35 | 35046 | 33454 | 110520764 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A04AA02 | ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Serotonin (5HT3) antagonists |
| CHEBI has role | CHEBI:48279 | serotonergic antagonist |
| CHEBI has role | CHEBI:50919 | antiemetic |
| FDA MoA | N0000175817 | Serotonin 3 Receptor Antagonists |
| FDA EPC | N0000175818 | Serotonin-3 Receptor Antagonist |
| MeSH PA | D000932 | Antiemetics |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D012702 | Serotonin Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| MeSH PA | D058831 | Serotonin 5-HT3 Receptor Antagonists |
Related Drugs by ATC class:
A04AA Serotonin (5HT3) antagonists 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Post-Operative Nausea and Vomiting | indication | 1488000 | |
| Chemotherapy-induced nausea and vomiting | indication | 236084000 | |
| Prevention of Post-Operative Nausea and Vomiting | indication | ||
| Prevention of Radiation-Induced Nausea and Vomiting | indication | ||
| Prolonged-Severe Nausea and Vomiting | off-label use | ||
| Hypokalemia | contraindication | 43339004 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Doxorubicin Induced Cardiomyopathy | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.79 | acidic |
| pKa2 | 9.5 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 3A | Ion channel | ANTAGONIST | Ki | 8.70 | WOMBAT-PK | CHEMBL | |||
| Solute carrier family 22 member 2 | Transporter | IC50 | 5.37 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.30 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Ki | 4.42 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 3B | Ion channel | Ki | 8.80 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.43 | WOMBAT-PK | |||||
| Neuronal acetylcholine receptor subunit alpha-3 | Ion channel | Ki | 4.17 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 3A | Ion channel | Ki | 8.40 | CHEMBL | |||||
| Serotonin 3 (5-HT3) receptor | Ion channel | Ki | 9.46 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020855 | VUID |
| N0000179527 | NUI |
| D00677 | KEGG_DRUG |
| 107007-99-8 | SECONDARY_CAS_RN |
| 4020855 | VANDF |
| 4023910 | VANDF |
| C0061863 | UMLSCUI |
| CHEBI:5537 | CHEBI |
| CWB | PDB_CHEM_ID |
| CHEMBL289469 | ChEMBL_ID |
| DB00889 | DRUGBANK_ID |
| CHEMBL1237080 | ChEMBL_ID |
| D017829 | MESH_DESCRIPTOR_UI |
| 5284566 | PUBCHEM_CID |
| 2300 | IUPHAR_LIGAND_ID |
| 6230 | INN_ID |
| WZG3J2MCOL | UNII |
| 142149 | RXNORM |
| 130105 | MMSL |
| 157872 | MMSL |
| 25895 | MMSL |
| 4344 | MMSL |
| 4801 | MMSL |
| d03171 | MMSL |
| 003975 | NDDF |
| 003976 | NDDF |
| 108424001 | SNOMEDCT_US |
| 108425000 | SNOMEDCT_US |
| 372489005 | SNOMEDCT_US |
| WZG3J2MCOL | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9744 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9745 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-546 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 26 sections |
| SUSTOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47426-101 | INJECTION | 10 mg | SUBCUTANEOUS | NDA | 28 sections |
| Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51991-735 | TABLET | 1 mg | ORAL | ANDA | 21 sections |
| Sancuso | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5985 | PATCH | 3.10 mg | TRANSDERMAL | NDA | 26 sections |
| Granisetron Hydrochloride | Human Prescription Drug Label | 1 | 55150-175 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| Granisetron Hydrochloride | Human Prescription Drug Label | 1 | 55150-176 | INJECTION, SOLUTION | 4 mg | INTRAVENOUS | ANDA | 24 sections |
| GRANISETRON HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-661 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 16 sections |
| GRANISETRON HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-661 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 16 sections |
| GRANISETRON HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-662 | INJECTION | 0.10 mg | INTRAVENOUS | ANDA | 16 sections |
| Granisetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-317 | INJECTION, SOLUTION | 0.10 mg | INTRAVENOUS | ANDA | 24 sections |
| Granisetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-318 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| Granisetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-319 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| Granisetron hydrochloride | Human Prescription Drug Label | 1 | 63850-0005 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 18 sections |
| SANCUSO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66220-637 | PATCH | 3.10 mg | TRANSDERMAL | NDA | 29 sections |
| Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-861 | INJECTION, SOLUTION | 0.10 mg | INTRAVENOUS | ANDA | 24 sections |
| Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-863 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-864 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
| Granisetron Hydrochloride | Human Prescription Drug Label | 1 | 67877-184 | TABLET | 1 mg | ORAL | ANDA | 16 sections |
| Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69452-350 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 20 sections |
| Granisol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 80056-801 | SOLUTION | 2 mg | ORAL | ANDA | 19 sections |